Literature DB >> 20483911

Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy.

Louise K Mercer1, Tonia L Moore, Hector Chinoy, Andrea K Murray, Andy Vail, Robert G Cooper, Ariane L Herrick.   

Abstract

OBJECTIVES: To quantify nailfold capillary density and dimensions in patients with idiopathic inflammatory myopathy (IIM) and compare them with those in healthy controls; to look for associations with microvascular disease in IIM; and to determine whether nailfold capillary density and dimensions change over time.
METHODS: Nailfold video microscopy (x300 magnification) was performed on 24 patients with IIM and 35 healthy controls. Capillary density and dimensions (total width and apical width) were quantified. Patients were clinically assessed and disease activity recorded using the Myositis Disease Activity Assessment Tool. Disease severity and physical function were assessed using the myositis damage index and Stanford HAQ, respectively. Findings were analysed using linear and logistic regression, adjusted for age and sex. In a subgroup of 16 patients with IIM and 27 controls, the process was repeated 6-12 months later and the results were analysed using Student's t-test.
RESULTS: Capillary density was lower and dimensions were higher in patients with IIM compared with healthy controls (P < 0.001 for all). Anti-Jo-1 antibody was associated with reduced capillary density. In the longitudinal cohort, the mean change in capillary density was -1.4 in patients vs -0.4 in controls (P = 0.07). Mean change in capillary dimensions did not differ between patients and controls, but some patients demonstrated pronounced changes in capillary morphology over time.
CONCLUSIONS: Reduced capillary density and increased dimensions in patients with IIM can be quantified using nailfold capillaroscopy, suggesting that nailfold capillaroscopy may be useful as an outcome measure of microvascular disease in studies of IIM.

Entities:  

Mesh:

Year:  2010        PMID: 20483911     DOI: 10.1093/rheumatology/keq051

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  Nailfold capillaroscopy in rheumatology: ready for the daily use but with care in terminology.

Authors:  Maurizio Cutolo; Sabrina Paolino; Vanessa Smith
Journal:  Clin Rheumatol       Date:  2019-08-08       Impact factor: 2.980

3.  Inflammatory myopathy and interstitial lung disease in antisynthetase syndrome with PL-7 antibody.

Authors:  Sílvia Aguiar Rosa; Paulo Barreto; Marisa Mariano; Isabel Baptista
Journal:  BMJ Case Rep       Date:  2014-10-07

4.  Nailfold capillaroscopic changes in dermatomyositis and polymyositis.

Authors:  A Manfredi; M Sebastiani; G Cassone; N Pipitone; D Giuggioli; M Colaci; C Salvarani; C Ferri
Journal:  Clin Rheumatol       Date:  2014-10-17       Impact factor: 2.980

Review 5.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 6.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

7.  Nailfold capillaroscopy changes with disease activity in patients with inflammatory myositis including overlap myositis, pure dermatomyositis, and pure polymyositis.

Authors:  Saeedeh Shenavandeh; Farideh Rashidi
Journal:  Reumatologia       Date:  2022-02-28

8.  Long-term follow-up of nailfold videocapillaroscopic changes in dermatomyositis versus systemic sclerosis patients.

Authors:  C Pizzorni; M Cutolo; A Sulli; B Ruaro; A C Trombetta; G Ferrari; G Pesce; V Smith; S Paolino
Journal:  Clin Rheumatol       Date:  2018-07-13       Impact factor: 2.980

Review 9.  [Gender-specific differences in capillaroscopy in healthy persons and patients with inflammatory rheumatic diseases].

Authors:  J G Richter; P Klein-Weigel; R Brinks; M Schneider; O Sander
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 10.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.